Our study initially provided evidence that CSRP1-knockdown suppressed COAD progression both in vitro and in vivo, suggesting that targeting CSRP1 may be a novel therapeutic direction for COAD treatment. The gene discussed is CSRP1; the disease is colon adenocarcinoma.